Pediatrix
PreclinicalBiologic
Pediatrix is one of 8 biologic programs targeting Bradycardia. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Bradycardia
#DrugCompanyPhaseTrials
1Atropen
FFresenius Kabi Oncology Ltd.
Approved
Ephedrine Sulfate
DDr. Reddys Laboratories, SA
Approved
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Robinul
Alnylam PharmaceuticalsPreclinical
Corlanor
AmgenPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Infanrix
GSKPreclinical
Pediatrix
AAmerican SIDS Institute
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pediatrix. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- AAmerican SIDS Institute